Abstracts tagged "muscle biopsy and myositis"

Abstract Number: 268 • 2016 ACR/ARHP Annual Meeting
Effect of Abatacept Treatment on T Cells in Muscle Tissue and Peripheral Blood in Polymyositis and Dermatomyositis Patients
Quan Tang¹, Daniel Ramsköld², Olga Krystufkova³, Herman F Mann⁴, Cecilia Wick⁵, Maryam Dastmalchi⁶, Peter Brodin⁷, Vivianne Malmström⁸, Jiri Vencovsky⁹ and Ingrid E. Lundberg⁶, ¹Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Stockholm, Sweden, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁵Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Abatacept (CTLA4-Ig), a blocking agent for T cell co-stimulation, has been proven beneficial in several autoimmune diseases. The aim of the study was to…
Abstract Number: 2322 • 2016 ACR/ARHP Annual Meeting
The Clinical Significance of Curvilinear Bodies on Ultrastructural Examination of Muscle
Thomas Khoo¹, Sophia Otto², Barbara Koszyka², Caroline Smith², Peter Blumbergs³, Sue Lester⁴ and Vidya Limaye⁵, ¹Medical Student, University of Adelaide, Adelaide, Australia, ²Anatomical Pathology, SA Pathology, Adelaide, Australia, ³Pathology, University of Adelaide, Adelaide, Australia, ⁴Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ⁵Rheumatology, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: The electronic database of muscle biopsies reported in the Anatomical Pathology Laboratory, SA Pathology was searched from 2006 to the present, to identify biopsies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].